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Abstract  
Introduction: COVID-19 is currently a global pandemic, and coagulation-related mortality has been widely 
reported in patients suffering from it. 
Objective: this article aimed to investigate the coagulation profile of COVID-19 patients.  
Methods: This was a cross-sectional study conducted using a retrospective research design. We recruited 
patients with COVID-19 admitted to a hospital from June 15th to July 7th, 2020. Upon patients’ entering a blood 
sample was drawn from each patient for assessing patient’s coagulation profile (PT, PTT, INR, Platelet 
count); and a chest high-resolution computed tomography (HRCT) scan was performed for each patient. The 
study patients were divided in to sever group (CO-RADS score 5) and non-sever group (CO-RADS score <5). 
Results: Thirty-six patients (20 males and 16 females) with a mean age of 54.7±17.5 years were studied. Of 
them, 11 cases (30.56%) had severe pulmonary involvement. Also, the coagulation profiles were longer in the 
severe group than non-sever group. As well, the means of platelet count that were 232.440 per microliter in 
the non-severe group and 289.180 per microliter in the severe and non-sever groups, respectively; but still not 
statistically significant (p>0.05). The Area under the ROC Curve (AUC) for PT and INR was 0.615 and 0.611, 
respectively. The AUC for platelet count was 0.680 (95% CI: 0.501 to 0.859) and had an acceptable 
discriminating power. 
Conclusions: In this study, we did not find any statistically significant relationship between the results of 
coagulation tests and the severity of pulmonary involvement according to HRCT scan findings in COVID-19 
patients. But further analyses suggest that, except PTT, the other coagulation tests (PT, INR, and platelet count) 
may discriminate severe COVID-19 patients. 
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INTRODUCTION
On 30 January 2020, the International Health 
Regulations (IHR) Emergency Committee of World 
Health Organization (WHO) declared a Public 
Health Emergency of International Concern 
(PHEIC) based on the growth rates in the reported 
COVID-19 cases in China and other regions of the 
world (1). The virus responsible for COVID-19 is a 
very pathogenic agent that primarily targets the 
human respiratory system (2). The clinical 
manifestations in these patients usually range from 
minor symptoms, such as fever and a dry cough 
that is sometimes accompanied by mild pneumonia 
and shortness of breath, to severe pneumonia, 
tachypnea, and disorders of gas exchange (3-5). 
About 5% of the patients with severe pulmonary 
involvement require mechanical ventilation 
and/or go into shock, and a large percentage of 
them suffer from multiple organ failure (6). There 
was some evidence indicating COVID-19 related 
abnormal level of coagulation markers and tests in 
the early reports from China. Han et al reported 
that preliminary characteristics of 99 patients 
admitted to hospitals in Wuhan showed that 6% 
had increased activated partial thromboplastin 
time (aPTT), 5% increased prothrombin time (PT), 
and 36% increased D-dimer and inflammatory 
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biomarkers including interleukin 6 (IL-6), 
increased erythrocyte sedimentation rate (ESR), 
and C-reactive protein (CRP) (7). Occurrence of 
some presentations such as frequent 
cardiovascular events in COVID-19 patients 
suggest that thrombotic events are probably 
involved in the disease course (8). But we are not 
aware that whether any relationship is present 
between the results of coagulation profile and 
severity of pulmonary involvement in COVID-19 
patients or not? Therefore, this article aimed to 
investigate the coagulation profile of COVID-19 
patients. 
Methods 
Study design and setting 
This was a cross-sectional study conducted using a 
retrospective research design. COVID-19 patients 
admitted from June 15th to July 7th in Peymanieh 
Hospital, Jahrom, Iran were studied. Written 
informed consent was obtained from the 
participant. The study proposal was approved by 
the Ethics Committee of Jahrom University of 
Medical Sciences (IR.JUMS.REC.1398.130). 
Study population 
Data were collected by census method. Inclusion 
criteria encompassed patients with positive 
reverse transcription polymerase chain 
reaction (RT-PCR) test for COVID-19. Exclusion 
criteria were patient’s lack of willingness to 
participate in the study or cooperate in the 
research until its end, and also history of 
underlying renal disease.  
Data Collection 
Upon patients’ entering COVID-19 emergency 
department, 5 mL blood was drawn from each 
patient for routine electrolyte measurements and 
also assessing patient’s coagulation profile (PT, 
PTT, INR, Platelet count); bedside blood glucose 
level was measured using a glucometer, and a chest 
high-resolution computed tomography (HRCT) 
scan was performed for each patient. An 
emergency medicine physician recorded the 
history of the underlying medical conditions and 
performed a physical examination.  
Definition 
The COVID-19 Reporting and Data System (CO-
RADS) was used to evaluate the severity of 
pulmonary damage. It is a five-point-scale that has 
been proposed to demonstrate the degree of 
pulmonary involvement in COVID-19 patients. The 
level of suspicion for pulmonary involvement 
ranges from very low (CO-RADS 1) to very high 
(CO-RADS 5) (9). In this study, the study patients 
were divided in to sever group (CO-RADS score 5) 
and non-sever group (CO-RADS score <5).  
Statistical Analysis   
Continuous variables were presented as mean± 
standard deviation (SD) and median with 
interquartile range (IQR). We used the Chi-squared 
or Fisher’s exact tests for assessing the distribution 
of categorical variables in the two groups based on 
CO-RADS categories <5 and 5. Also, the difference 
in the means of numerical variables in the two 
groups was assessed by Student's t-test. A p-value 
lower than 0.05 was considered statistically 
significant. The power of the coagulation tests to 
discriminate severe COVID-19 was assessed using 
the area under the ROC curve (AUC). The best cut-
off point of platelet count for discriminating severe 
COVID-19 was determined using the J-Youden 
statistics. Sensitivity and specificity with a 95% 
confidence interval were presented for the best 
suggested cut-off point. All analyzes were 
performed using the STATA software version 15. 
RESULTS 
Thirty-six patients (20 males and 16 females) with 
a mean age of 54.7±17.5 years were studied. Of 
them, 11 cases (30.56%) had severe pulmonary 
involvement based on HRCT scan findings (Figure 
1). Table 1 presents demographic characteristics 
and presentation symptoms in the patients by CO-
RADS category. Generally, the most common 
symptoms on admission were fever (55.6%), 
followed by shortness of breath (47.2%) and cough 
(41.7%). 
Table 2 reports the means of assessed laboratory 
variables in the COVID-19 patients by CO-RADS 
category. The glucose (127.82 mg/dL vs 113.60 
mg/dL) and BUN (19.45 mg/dL vs 17.60 mg/dL) 
levels were higher in severe patients than in the 
non-severe patients; However, the difference in 
CO-RADS categories was not statistically significant 
(p>0.05). Also, the coagulation profiles were longer 
in the severe group than non-sever group.  
 
Figure 1: The distribution of studied COVID-19 patients 
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Table 1: The basic characteristics and symptoms by CO-RADS category. 
Variable Total (n=36) 
CO-RADS 
<5 (n=25) 5 (n=11) 
Age, Mean±SD 54.72±17.55 53.76±19.11 56.91±13.91 
Age category, n (%)    
     Under 30 years 2 (5.6) 2 (8.0) 0 (0.0) 
     30 to 60 years 20 (55.6) 14 (56.0) 6 (54.5) 
     Over 60 years 14 (38.9) 9 (36.0) 5 (45.5) 
Sex, n (%)    
     Male 20 (55.6) 14 (56.0) 6 (54.5) 
     Female 16 (44.4) 11 (44.0) 5 (45.5) 
Symptoms, n (%)    
     Cough  15 (41.7) 8 (32.0) 7 (63.6) 
     Shortness of breath 17 (47.2) 12 (48.0) 5 (45.5) 
     Fatigue 3 (8.3) 2 (8.0) 1 (9.1) 
     Fever 20 (55.6) 13 (52.0) 7 (63.6) 
     Abdominal pain 2 (5.6) 1 (4.0) 1 (9.1) 
     Gastroenteritis 2 (5.6) 2 (8.0) 0 (0.0) 
 
Table 2: The differences in the means of laboratory variables in COVID-19 patients by CO-RADS category 
Variable Total (n=36) 
CO-RADS 
P-value 
<5 (n=25) 5 (n=11) 
Magnesium (Mg) 1.88±0.20 1.92±0.21 1.80±0.17) 0.115 
Phosphor (P) 3.70±1.38 3.71±1.50 3.66±1.11 0.924 
Blood urea nitrogen (BUN) 18.17±10.35 17.60±8.56 19.45±14.0 0.627 
Creatinine (Cr) 1.39±0.88 1.38±0.92 1.44±0.80 0.852 
Potassium (K) 4.10±0.57 4.08±0.61 4.14±0.28 0.802 
Sodium (Na) 143.69±46.48 147.04±55.74 136.09±3.53 0.523 
Albumin 3.36±0.39 3.34±0.43 3.38±0.30 0.793 
Glucose 117.94±38.24 113.60±26.68 127.82±57.04 0.445 
PT 14.72±1.44 14.57±1.41 15.05±1.52 0.361 
PTT 31.97±6.39 31.72±7.07 32.52±4.74 0.737 
INR 1.09±0.11 1.08±0.10 1.12±0.11 0.371 
Platelets count 249.78±116.14 232.44±113.70 289.18±117.14 0.181 
PT: prothrombin time; PTT: Partial thromboplastin time; INR: International normalized ratio 
 
Figure 2: The distribution of coagulation marker levels by CO-RADS category 
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As well, the means of platelet count that were 
232.440 per microliter in the non-severe group and 
289.180 per microliter in the severe and non-sever 
groups, respectively; but still not statistically 
significant. 
The Box plot of coagulation tests showed that the 
levels of all markers were higher in the severe 
patients (CO-RADS 5) compared to the mild ones 
(CO-RADS 2, 3) and moderate patients (CO-RADS 
4) (Figure 2).  
The median (interquartile range; IQR) of PT was 
13.5 (2.8), 14.3 (1.1), and 15.1 (2.1) in mild, 
moderate, and severe groups, respectively. Also, 
the median (IQR) of the INR was 1.0 (0.21), 1.06 
(0.07), and 1.12 (0.16) and for platelet count, it was 
176.0 (81.0), 192.0 (138.3), 273.0 (201.0) in mild, 
moderate, and severe groups, respectively.  
The area under the ROC curve of PTT was lower 
than that of the other tests and could not 
discriminate severe COVID-19 based on category 5 
of CO-RADS. The AUC of PT and INR was 0.615 and 
0.611, respectively. The AUC of platelet count was 
0.680 (95% CI: 0.501 to 0.859) and had acceptable 
discrimination power (Table 3, Figure 3). The best 
cut-off point of platelet count for discriminating 
severe COVID-19 was >208,000 per microliter; and 
the sensitivity and specificity for this cut-off point 
were 72.73% (95% CI: 39.0% to 94.0%) and 64.0% 
(95% CI: 42.5% to 82.0%), respectively.  
DISCUSSION 
In this study, we investigated the coagulation 
profile of COVID-19 patients and found that 
although there were some differences in severe 
and non-sever cases, but they were not statistically 
significant. However, except PTT, the other 
coagulation tests (PT, INR, and platelet count) may 
discriminate severe COVID-19 patients. 
The study by Lodigiani et al. reported that 
coagulation and cardiac biomarkers increased in 
COVID-19 patients. This finding indicated 
inflammation manifested by coagulation activation 
and endothelial dysfunction (10). According to 
Zhou et al. findings, the complication rate in COVID-
19 hospitalized patients for venous and arterial 
thromboembolism was approximately 8% despite 
anticoagulant prophylaxis (8). In contrast with 
Lodigiani’s findings, significant relationship was 
not observed between the results of coagulation 
tests and the severity of pulmonary involvement in 
COVID-19 patients in the present study. However, 
there may be dissimilarities between the results 
due to geographical and ethnic differences 
between our patients and those examined by 
Lodigiani. In another study, it was reported that the 
difference in the median levels of D-dimer was 
higher between non-surviving and surviving 
COVID-19 patients than between acute respiratory 
distress syndrome (ARDS) and non-ARDS patients; 
It indicates that disseminated intravascular 
coagulation (DIC)-related complications may lead 
to death in a subset of COVID-19 patients 
independently of ARDS (11). In the present study, 
D-dimer levels were not available for all patients 
because, during the first peak of COVID-19 in Iran, 
in which the number of patients was low, this 
marker was not routinely tested. On the other 
hand, the study by Liu et al. showed no significant 
correlation between COVID-19 and 
thrombocytopenia (12). In the present study, the 
mean platelet count was a bit higher in patients 
with higher CO-RADS scores, which somehow in 
line with the results of the study by Liu et al. One 
recent report has suggested that immune 
thrombocytopenia (ITP) may be associated with 
COVID-19 infection (13). ITP is a rare autoimmune 
disease, characterized by a platelet count of < 100 
× 109/L, that increases the risk of internal bleeding 
(14). ITP has been reported not only during active 
COVID‐19 infection but also up to 10 days after the 
clinical COVID‐19 symptoms have subsided. 
Diagnosis of COVID-19-related ITP may be difficult 
due to several other potential factors, including 
coagulation activation by COVID-19 which leads to 
DIC and subsequent thrombocytopenia. Also, 
Table 3: The area under the ROC curve (with 95% CI) of 
coagulation markers for severe CO-RADS 
Marker AUC (95% CI) P-value 
PT 0.615 (0.404 to 825) 0.279 
PTT 0.489 (0.277 to 0.701) 0.918 
INR 0.611 (0.399 to 0.823) 0.295 
Platelets count 0.680 (0.501 to 859) 0.089 
PT: prothrombin time; PTT: Partial thromboplastin time; 
INR: International normalized ratio 
 
 
Figure 3: The area under the ROC curve of coagulation 
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suggested treatments for COVID-19 such as 
heparin, azithromycin, and hydroxychloroquine 
may cause thrombocytopenia (15, 16).  
Limitations 
The small sample size of the present study is its 
main limitation. As a result, we found wide 
confidence intervals for AUC and other indices such 
as sensitivity and specificity. Therefore, the result 
of this study should be interpreted with caution 
and a larger sample size study is needed to confirm 
or disprove the hypothesis presented in this study.  
CONCLUSIONS 
In this study, we did not find any statistically 
significant relationship between the results of 
coagulation tests and the severity of pulmonary 
involvement according to HRCT scan findings in 
COVID-19 patients. But further analyses suggest 
that, except PTT, the other coagulation tests may 
discriminate severe COVID-19 patients. 
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